非小细胞肺癌脑转移的酪氨酸激酶抑制剂治疗:放射科医师入门
本文为非小细胞肺癌脑转移的综述,旨在为放射科医师提供全身治疗(重点为酪氨酸激酶抑制剂)的指南,描述血脑屏障在全身治疗开发中的关键作用,并概述当前基于影像的疗效标准,重点讨论神经肿瘤疗效评估(RANO)标准在评估接受全身及传统治疗患者中的应用。
要点
- 酪氨酸激酶抑制剂是NSCLC脑转移全身治疗的重要组成部分。
- 血脑屏障是全身治疗开发的关键因素。
- RANO标准可用于评估全身及传统治疗的疗效。
核心结论
- 本综述旨在指导放射科医师理解全身治疗(尤其酪氨酸激酶抑制剂)在NSCLC脑转移中的作用,并强调RANO标准在疗效评估中的应用。
研究设计与样本
- 综述文章,检索范围与纳入文献未在原文中报告。
诊断标准与关键数值
- 文中汇总了当前基于影像的疗效评估指南,并讨论了RANO标准在评估接受全身及传统治疗患者中的应用。
临床应用与阅片要点
- 放射科医师可参考本文了解全身治疗在NSCLC脑转移中的作用,并应用RANO标准进行疗效评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Treatment options for patients who develop brain metastases secondary to non-small-cell lung cancer have rapidly expanded in recent years. As a key adjunct to surgical and radiation therapy options, systemic therapies are now a critical component of the oncologic management of metastatic CNS disease in many patients with non-small-cell lung cancer. The aim of this review article was to provide a guide for radiologists, outlining the role of systemic therapies in metastatic non-small-cell lung cancer, with a focus on tyrosine kinase inhibitors. The critical role of the blood-brain barrier in the development of systemic therapies will be described. The final sections of this review will provide an overview of current imaging-based guidelines for therapy response. The utility of the Response Assessment in Neuro-Oncology criteria will be discussed, with a focus on how to use the response criteria in the assessment of patients treated with systemic and traditional therapies.
引用
- Dodson C, Richards TJ, Smith DA, et al. Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists. AJNR Am J Neuroradiol. 2020. PMID: 32217548. doi:10.3174/ajnr.A6477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。